NASA astronauts Butch Wilmore and Suni Williams are steadily recovering after spending nine unexpected months aboard the International Space Station (ISS) due to issues with Boeing’s Starliner capsule. Initially intended for an eight-day test flight, the mission extended when Starliner experienced propulsion problems that forced NASA to return the capsule uncrewed in 2023.
The astronauts returned to Earth in March 2025 and have since undergone intensive physical therapy to readjust to gravity. Wilmore, 62, noted the difficulties of re-adapting to Earth's conditions, saying, “Gravity stinks for a period.” Williams, 59, echoed the challenges, highlighting muscle fatigue and delayed energy recovery. Both astronauts spent about two hours daily with NASA’s reconditioning specialists during a standard 45-day rehab period.
Despite lingering issues, such as neck pain for Wilmore and fatigue for Williams, both are now supporting Boeing and NASA operations, helping evaluate the Starliner program and contributing to ISS-related research. Wilmore noted that some of his preexisting physical pain vanished in microgravity but returned immediately upon splashdown.
Boeing has already incurred over $2 billion in costs developing Starliner and is awaiting a key decision from NASA: whether to mandate another uncrewed flight before resuming crewed missions. Williams supports the idea, citing the cautious approach taken by SpaceX and Russia in launching uncrewed missions before sending astronauts.
NASA expects to complete tests of Starliner over the summer, which will determine if it’s ready to fly humans again. Williams and Wilmore continue to be key figures in that assessment as Boeing aims to regain trust in its human spaceflight program.
The Starliner setback adds to Boeing’s ongoing challenges, contrasting with the consistent performance of rival capsules developed by SpaceX. NASA’s upcoming decision will be pivotal for Boeing’s future in space exploration.


Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
Neuralink Expands Brain Implant Trials with 12 Global Patients
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns
EssilorLuxottica Bets on AI-Powered Smart Glasses as Competition Intensifies
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure
Australia’s Under-16 Social Media Ban Sparks Global Debate and Early Challenges
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 



